Drug Approval | January 09, 2026
BeOne Medicines wins first-in-world nod for Sonrotoclax in China
The approval is backed by data showing deep, durable responses and manageable tolerability
The approval is backed by data showing deep, durable responses and manageable tolerability
NTX-253 is a potent, selective, orally available positive allosteric modulator (PAM) of the muscarinic M4 receptor
Phase 3 study met all primary and secondary endpoints, demonstrating superior convenience, strong efficacy, and excellent safety versus conventional ondansetron injections
The guidelines also support reusing tenofovir and abacavir in later regimens for improved outcomes, cost savings, and programmatic efficiency
This drug candidate, which is currently progressing through pivotal clinical studies, has the potential to become the first add-on therapy for schizophrenia patients who do not respond adequately
Ventyx's clinical pipeline includes multiple small molecules with potential for oral therapies addressing chronic inflammation
The therapy was well tolerated through Week 24, with a safety profile consistent with Alumis’ Phase 2 data
The trial aims to measure AF burden—the percentage of time patients spend in arrhythmia—as its primary efficacy endpoint
Sevabertinib is an oral, reversible tyrosine kinase inhibitor (TKI) that directly targets HER2 mutations
The privately held biotech brings a first-in-class oncology program focused on small molecule–targeted protein degradation
Subscribe To Our Newsletter & Stay Updated
